05/24/2017

FDA approved KEYTRUDA® (pembrolizumab) for adult and pediatric patients with MSI-H or dMMR.

The FDA has granted accelerated approval to KEYTRUDA^® (pembrolizumab) for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. 

This is the FDA's first tissue/site-agnostic approval.

For more information, click here.